Vanda Pharmaceuticals (VNDA) Q2 2025: FNAPT Prescriptions Surge 24% as Sales Force Expansion Accelerates
Vanda Pharmaceuticals’ Q2 2025 was defined by a step-change in FNAPT prescription growth, propelled by aggressive sales force expansion and a broadened commercial footprint. While FNAPT’s bipolar launch drove volume gains, legacy Hetlios and newly launched Ponvory faced distinct revenue pressures and variability. Investors should watch for the company’s ability to translate commercial investments into sustainable top-line growth as product launches mature and pipeline catalysts approach in 2026.
Summary
- FNAPT Demand Inflection: Prescription and new patient metrics hit record highs following a 300-rep sales force rollout.
- Product Mix Volatility: Hetlios volume declines and Ponvory launch friction offset headline revenue progress.
- Pipeline-Driven Optionality: Six potential commercial products by 2026 could reshape Vanda’s revenue base.
Performance Analysis
Vanda’s Q2 2025 results reveal a business in rapid commercial transition, with FNAPT, its flagship antipsychotic, delivering a 27% revenue jump year-over-year on the back of the bipolar I disorder launch. The company’s aggressive sales force expansion to 300 representatives and a 400%+ increase in prescriber calls over the prior year fueled a 24% rise in total FNAPT prescriptions and a >200% surge in new-to-brand RX, clear evidence of commercial momentum. Hetlios, the legacy sleep-wake disorder drug, saw a 13% YoY revenue decline amid ongoing generic encroachment and inventory drawdowns, while Ponvory, the MS therapy acquired in late 2023, experienced an 18% YoY sales drop but set a new high for new patient prescriptions since Vanda’s launch.
Operating expenses soared 50% YoY, driven by sales force buildout, marketing, and R&D tied to new launches and pipeline assets. This investment-heavy period resulted in a net loss of $27.2 million for the quarter, widening from a $4.5 million loss a year ago. Cash burn accelerated, with $325.6 million remaining at quarter end, down $15.4 million sequentially. Management reiterated full-year revenue guidance of $210-250 million, but flagged that FNAPT and Ponvory will need to outpace Hetlios erosion to avoid the low end of the range.
- FNAPT Commercial Expansion: Sales force tripling and DTC campaigns drove prescription growth and market share gains.
- Hetlios Generic Pressure: Ongoing volume loss and inventory destocking signal sustained headwinds.
- Ponvory Launch Dynamics: Slow but steady new patient uptake, with sales force reset underway to address neurology access barriers.
Underlying performance signals a company betting heavily on near-term commercial scale and long-term pipeline optionality, but facing short-term margin and cash flow compression as legacy products fade.
Executive Commentary
"FNAP revenue increased by 27% compared to the same period in the prior year, driven by the launch of the bipolar one indication. FNAP is now promoted in the U.S. across all 50 states with a dedicated sales force of approximately 300 representatives."
Dr. Mahalis Polymeropoulos, President, Chief Executive Officer, and Chairman of the Board
"Operating expenses in the second quarter of 2025 were $91.1 million compared to $60.6 million in the second quarter of 2024. The $30.5 million increase was primarily driven by higher SG&A expenses related to spending on Vanda's commercial products as a result of the commercial launches of Phenaptin Bipolar Disorder and Ponvoria Multiple Sclerosis and higher R&D expenses."
Kevin Moran, Chief Financial Officer
Strategic Positioning
1. FNAPT as the Growth Engine
FNAPT, Vanda’s lead antipsychotic, is now the company’s core revenue driver, accounting for the majority of growth following its bipolar I disorder indication launch. The sales force scale-up to 300 reps and national DTC (direct-to-consumer) campaigns have yielded record new patient starts and prescription volumes. This commercial infrastructure is designed for transferability, with management noting the FNAPT platform can be leveraged for future launches, notably Bisanti.
2. Portfolio Diversification and Launch Risk
Vanda is actively diversifying its revenue base, with Ponvory (MS therapy) and Hetlios (sleep-wake disorder) providing additional branded product streams. However, both products are under pressure—Hetlios from generics and Ponvory from launch friction and payer mix headwinds. Ponvory’s performance is expected to be steady rather than explosive, with sales force restructuring underway to improve neurologist access and prescription velocity.
3. Pipeline Optionality and Regulatory Milestones
Pipeline execution remains a strategic pillar, with Bisanti (milsaperidone) awaiting FDA review for bipolar I and schizophrenia (PDUFA in February 2026), and Tridiputant under review for motion sickness (PDUFA December 2025). The Phase 3 MDD (major depressive disorder) study for Bisanti is ongoing, with results expected in 2026. Management projects up to six commercial products by 2026, a potential step-change in revenue composition and scale.
4. Commercial Leverage and Gross-to-Net Reset
Bisanti’s launch could unlock a step-function in net revenue capture, as Medicaid rebates reset to statutory minimums, unlike FNAPT which faces a 100% Medicaid rebate after years of price increases. Management expects Bisanti’s gross-to-net to be meaningfully more favorable, potentially boosting profitability even with similar patient volumes.
5. Capital Allocation Amid Cash Burn
Vanda’s elevated SG&A and R&D spend reflect a deliberate strategy to “buy” commercial scale and future optionality, but at the cost of near-term losses and cash drawdown. Management’s guidance assumes continued investment, with the caveat that slower FNAPT ramp or faster Hetlios decline could push results to the low end of guidance and pressure the cash runway.
Key Considerations
Q2 2025 marked a pivotal quarter for Vanda as it doubled down on commercial execution and pipeline advancement, but investors face a complex risk-reward as the company transitions from legacy reliance to a multi-product, launch-driven model.
Key Considerations:
- FNAPT Commercial Traction: Prescription and new patient growth rates are strong, but sustainability as DTC spend plateaus remains to be proven.
- Hetlios Decline Pace: Ongoing generic erosion and inventory normalization could create further revenue volatility.
- Ponvory Launch Curve: Neurology access challenges and payer mix may limit near-term upside despite record new patient starts.
- Pipeline Catalysts: Bisanti and Tridiputant regulatory outcomes in 2026 could materially reshape the portfolio, but development and approval risks remain.
- Cash Burn vs. Growth: Heavy SG&A and R&D investments are justified only if commercial launches scale as projected; otherwise, the cash runway could shorten materially.
Risks
Vanda faces concentrated risk from execution on new launches, especially as Hetlios revenues erode and Ponvory’s trajectory remains uncertain. Regulatory delays or negative outcomes for Bisanti or Tridiputant could undermine future growth expectations. Cash burn is significant and may accelerate if sales ramp lags or SG&A remains elevated, potentially pressuring capital allocation flexibility. Ongoing disputes, such as the $3 million Ponvory gross-to-net issue, highlight commercial complexity and revenue recognition risk.
Forward Outlook
For Q3 2025, Vanda guided to:
- Continued sequential FNAPT growth as sales force productivity matures
- Ongoing Ponvory sales force expansion to 50 reps and launch optimization
For full-year 2025, management reiterated guidance:
- Total revenue of $210–250 million
- Year-end cash of $280–320 million
Management emphasized that:
- FNAPT and Ponvory revenue will be back-weighted, with acceleration expected in the second half
- Hetlios revenue variability and decline could offset growth if generic pressure intensifies
Takeaways
Vanda’s Q2 2025 showcased clear commercial momentum in FNAPT, but also exposed the company’s reliance on successful execution of new launches and pipeline catalysts to offset legacy product fade and elevated cash burn.
- FNAPT Execution: Sales force scale and DTC investment are yielding prescription growth, but the conversion to durable, profitable revenue remains the key watchpoint.
- Portfolio Transition: Hetlios and Ponvory volatility underscores the challenge of managing a multi-product portfolio in transition, with pipeline success critical for medium-term upside.
- 2026 Pipeline Milestones: Investors should closely track Bisanti and Tridiputant regulatory progress, as these events will determine whether Vanda’s investment cycle translates into a sustainable growth platform.
Conclusion
Vanda’s Q2 2025 results reflect a company in the midst of an aggressive commercial and pipeline transformation. FNAPT’s prescription surge is promising, but the path to portfolio diversification and cash flow stability depends on flawless execution of multiple concurrent launches and regulatory milestones.
Industry Read-Through
Vanda’s experience highlights the commercial lift required to drive uptake in CNS (central nervous system) markets, where sales force scale and DTC spend can move the needle, but only with sustained execution. The Medicaid rebate reset opportunity for new chemical entities like Bisanti is instructive for other specialty pharma players managing legacy price inflation. Generic erosion and launch friction remain persistent industry themes, reinforcing the need for pipeline depth and commercial agility in specialty and orphan drug markets.